Hepatitis C and renal transplantation in era of new antiviral agents

Table 4 Main literature studies with direct acting antiviral therapy in patients with chronic hepatitis C and renal dysfunction

Ref.	Title	Journal	Year
[62]	Efficacy of direct-acting antiviral combination for patients with HCV genotype 1 infection and severe renal impairment or end-stage renal disease	Gastroenterology	2016
[63]	Glecaprevir and Pibrentasvir in patients with HCV and severe renal impairment	N Engl J Med	2017
[64]	Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with HCV genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): A combination phase 3 study	Lancet	2015
[65]	Elbasvir plus grazoprevir in patients with HCV infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomized, double-blind, placebo-controlled trial	Lancet Gastroenterol Hepatol	2017
[70]	Use of sofosbuvir-based direct-acting antiviral therapy for HCV infection in patients with severe renal insufficiency	Infect Dis	2015
[71]	Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of hepatitis C in patients with end stage renal disease	J Hepatol	2015
[72]	Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR < 30 mL/min	Liver Int	2016
[74]	Use of direct-acting agents for HCV-positive kidney transplant candidates and kidney transplant recipients	Transpl Int	2016
[75]	Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function	Liver Int	2016

HCV: Hepatitis C virus.